BioCentury is featuring Inositec in this week’s emerging company profile. Read the article here (requires subscription).
- Preclinical work on INS-3001 efficacy in renal fibrosis published
- Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
- Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
- Preclinical work on calcium oxalate inhibitors for renal indications published
- Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications